Name Olmesartan
Classes Cardiovascular Agent
Antihypertensive
Angiotensin Receptor Blocker (ARB)
Diseases Cardiovascular Disease
Hypertension (High Blood Pressure)

Olmesartan

Olmesartan belongs to a class of drugs called Angiotensin II receptor blockers or ARBs. It prevents Angiotensin II from binding to Angiotensin receptor 1 and hence antagonizing it's effects.

The drug Olmesartan is used to treat hypertension. It can be taken alone or with other antihypertensive medications.

  • Olmesartan is available as tablets.

Adult dosage:

  • Olmesartan 10 mg once daily is the recommended beginning dose. The dose of Olmesartan may be increased to 20 mg once daily in people whose blood pressure is not properly managed at this dose. If further blood pressure control is needed, the dose of Olmesartan can be increased to a maximum of 40 mg per day, or hydrochlorothiazide therapy can be added.
  • Due to limited experience with larger dosages in this patient group, the maximum dose in patients with mild to moderate renal impairment (creatinine clearance of 20–60 mL/min) is 20 mg Olmesartan once day. Because there is relatively limited experience in this patient group, the use of Olmesartan in patients with severe renal impairment (creatinine clearance 20 mL/min) is not suggested.

Pediatric Dosage:

  • In children aged 6 to less than 18 years, a starting dose of 10 mg olmesartan once daily is recommended. The dose of olmesartan may be increased to 20 mg once daily in children whose blood pressure is not well managed at this dose.

 

Common side effects associated with Omlesartan are as follows-

  • Headache
  • Dizziness
  • Hyperlipidemia
  • Hyperglycemia
  • Bronchitis
  • Pharyngitis
  • Abdominal pain
  • Nausea

 

  • Changes in renal function may be expected in susceptible patients treated with Olmesartan as a result of suppressing the renin-angiotensin-aldosterone system.
  • Treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been linked to oliguria and/or progressive azotemia, as well as (rarely) acute renal failure and/or death in patients whose renal function may be dependent on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure). Patients receiving Olmesartan could expect similar results.

Contraindication

  • Olmesartan is contraindicated in patients who are hypersensitive to Olmesartan or other ARBs, such as-
  • Olmesartan should not be co-administered with the following drug in patients with diabetes and renal impairment-

Omlesartan is contraindicated in the following health conditions-